NOMURA HOLDINGS INC-SPON ADR (NMR) Stock Fundamental Analysis
NYSE:NMR - US65535H2085 - ADR
7.37 USD
+0.16 (+2.22%)
7.37 USD
0 (0%)
NMR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 238 industry peers in the Capital Markets industry. NMR may be in some trouble as it scores bad on both profitability and health. NMR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year NMR was profitable.
NMR had a negative operating cash flow in the past year.
Each year in the past 5 years NMR has been profitable.
The reported operating cash flow has been mixed in the past 5 years: NMR reported negative operating cash flow in multiple years.
1.2 Ratios
NMR has a Return On Assets of 0.60%. This is in the lower half of the industry: NMR underperforms 68.35% of its industry peers.
NMR has a Return On Equity (9.82%) which is comparable to the rest of the industry.
NMR has a Return On Invested Capital of 0.62%. This is in the lower half of the industry: NMR underperforms 71.31% of its industry peers.
NMR had an Average Return On Invested Capital over the past 3 years of 0.41%. This is significantly below the industry average of 7.58%.
The 3 year average ROIC (0.41%) for NMR is below the current ROIC(0.62%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | 9.82% | ||
| ROIC | 0.62% |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.41%
ROIC(5y)0.41%
1.3 Margins
NMR has a worse Profit Margin (7.19%) than 63.29% of its industry peers.
NMR's Profit Margin has declined in the last couple of years.
NMR has a worse Operating Margin (9.96%) than 68.35% of its industry peers.
In the last couple of years the Operating Margin of NMR has declined.
The Gross Margin of NMR (39.95%) is worse than 63.29% of its industry peers.
In the last couple of years the Gross Margin of NMR has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.96% | ||
| PM (TTM) | 7.19% | ||
| GM | 39.95% |
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
2. Health
2.1 Basic Checks
The number of shares outstanding for NMR has been reduced compared to 1 year ago.
Compared to 5 years ago, NMR has less shares outstanding
The debt/assets ratio for NMR has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -0.24, we must say that NMR is in the distress zone and has some risk of bankruptcy.
NMR has a Altman-Z score of -0.24. This is in the lower half of the industry: NMR underperforms 75.53% of its industry peers.
NMR has a Debt/Equity ratio of 10.44. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 10.44, NMR is not doing good in the industry: 88.61% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.44 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.24 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
NMR has a Current Ratio of 0.23. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.23, NMR is doing worse than 86.92% of the companies in the same industry.
A Quick Ratio of 0.23 indicates that NMR may have some problems paying its short term obligations.
NMR has a Quick ratio of 0.23. This is amonst the worse of the industry: NMR underperforms 86.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.23 | ||
| Quick Ratio | 0.23 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 79.28% over the past year.
Measured over the past years, NMR shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.96% on average per year.
The Revenue has grown by 13.94% in the past year. This is quite good.
NMR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.39% yearly.
EPS 1Y (TTM)79.28%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%62.38%
Revenue 1Y (TTM)13.94%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-4.36%
3.2 Future
The Earnings Per Share is expected to grow by 0.23% on average over the next years.
NMR is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -6.53% yearly.
EPS Next Y-2.18%
EPS Next 2Y-0.93%
EPS Next 3Y0.23%
EPS Next 5YN/A
Revenue Next Year-19.63%
Revenue Next 2Y-10.67%
Revenue Next 3Y-6.53%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 8.19 indicates a reasonable valuation of NMR.
Compared to the rest of the industry, the Price/Earnings ratio of NMR indicates a rather cheap valuation: NMR is cheaper than 83.97% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.24. NMR is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 9.34, which indicates a very decent valuation of NMR.
Based on the Price/Forward Earnings ratio, NMR is valued a bit cheaper than 79.75% of the companies in the same industry.
NMR's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.81.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.19 | ||
| Fwd PE | 9.34 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NMR indicates a somewhat cheap valuation: NMR is cheaper than 70.89% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 22.79 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)0.75
EPS Next 2Y-0.93%
EPS Next 3Y0.23%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.07%, NMR is a good candidate for dividend investing.
NMR's Dividend Yield is comparable with the industry average which is at 8.00.
Compared to an average S&P500 Dividend Yield of 2.34, NMR pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.07% |
5.2 History
On average, the dividend of NMR grows each year by 15.59%, which is quite nice.
NMR has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of NMR decreased in the last 3 years.
Dividend Growth(5Y)15.59%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
NMR pays out 33.03% of its income as dividend. This is a sustainable payout ratio.
NMR's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP33.03%
EPS Next 2Y-0.93%
EPS Next 3Y0.23%
7.37
+0.16 (+2.22%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners38.49%
Inst Owner Change4.93%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap21.62B
Analysts69.23
Price Target7.05 (-4.34%)
Short Float %0.06%
Short Ratio2.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.07% |
Yearly Dividend0.27
Dividend Growth(5Y)15.59%
DP33.03%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)23.99%
Min EPS beat(2)-10.21%
Max EPS beat(2)58.19%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.3%
PT rev (3m)-4.11%
EPS NQ rev (1m)0.65%
EPS NQ rev (3m)180.17%
EPS NY rev (1m)2.91%
EPS NY rev (3m)4.58%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-16.55%
Revenue NY rev (3m)-16.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.19 | ||
| Fwd PE | 9.34 | ||
| P/S | 0.68 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.93 | ||
| P/tB | 0.93 | ||
| EV/EBITDA | 22.79 |
EPS(TTM)0.9
EY12.21%
EPS(NY)0.79
Fwd EY10.71%
FCF(TTM)-3.55
FCFYN/A
OCF(TTM)-1.56
OCFYN/A
SpS10.86
BVpS7.96
TBVpS7.96
PEG (NY)N/A
PEG (5Y)0.75
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | 9.82% | ||
| ROCE | 1.58% | ||
| ROIC | 0.62% | ||
| ROICexc | 0.68% | ||
| ROICexgc | 0.69% | ||
| OM | 9.96% | ||
| PM (TTM) | 7.19% | ||
| GM | 39.95% | ||
| FCFM | N/A |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.41%
ROIC(5y)0.41%
ROICexc(3y)0.45%
ROICexc(5y)0.45%
ROICexgc(3y)0.46%
ROICexgc(5y)0.46%
ROCE(3y)1.07%
ROCE(5y)1.07%
ROICexcg growth 3Y16.49%
ROICexcg growth 5Y7.83%
ROICexc growth 3Y15.92%
ROICexc growth 5Y7.53%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
F-Score6
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.44 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 67.92 | ||
| Cap/Depr | 1410.99% | ||
| Cap/Sales | 18.37% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.23 | ||
| Quick Ratio | 0.23 | ||
| Altman-Z | -0.24 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)988.49%
Cap/Depr(5y)668.06%
Cap/Sales(3y)14.69%
Cap/Sales(5y)11.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.28%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%62.38%
EPS Next Y-2.18%
EPS Next 2Y-0.93%
EPS Next 3Y0.23%
EPS Next 5YN/A
Revenue 1Y (TTM)13.94%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-4.36%
Revenue Next Year-19.63%
Revenue Next 2Y-10.67%
Revenue Next 3Y-6.53%
Revenue Next 5YN/A
EBIT growth 1Y72.34%
EBIT growth 3Y27.7%
EBIT growth 5Y13.71%
EBIT Next Year20468.4%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-122.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-883.38%
OCF growth 3YN/A
OCF growth 5YN/A